keyword
MENU ▼
Read by QxMD icon Read
search

Waldenstroms

keyword
https://www.readbyqxmd.com/read/29780960/waldenstrom-macroglobulinemia-involving-the-superior-rectus-muscle
#1
J B Hellman, G J Harocopos, L K Lin
Purpose: We present the first reported case of Waldenstrom macroglobulinemia in the right superior rectus causing diplopia. Observations: A 72-year-old man with a 6-month history of untreated asymptomatic Waldenstrom macroglobulinemia presented with 2 years of diagonal binocular diplopia that was previously thought to be due to ocular myasthenia gravis. Examination showed mild right proptosis and right hypotropia, and MRI revealed a focal lesion of the right superior rectus muscle...
June 2018: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29773590/impact-of-ibrutinib-dose-intensity-on-patient-outcomes-in-previously-treated-waldenstr%C3%A3-m-macroglobulinemia
#2
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, Toni E Dubeau, Lian Xu, Guang Yang, Zachary R Hunter, Ranjana Advani, Lia Palomba, Steven P Treon
No abstract text is available yet for this article.
May 17, 2018: Haematologica
https://www.readbyqxmd.com/read/29768934/a-safety-profile-of-medications-used-to-treat-waldenstr%C3%A3-m-s-macroglobulinemia
#3
Ramón García-Sanz, Cristina Jiménez, Verónica González de la Calle, María Eugenia Sarasquete
Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disease with serum IgM monoclonal component and bone marrow infiltration by lymphoplasmacytic lymphoma. Traditional therapy was based on that regimens used for closely related entities, such as chronic lymphocytic leukemia or multiple myeloma. This resulted in a lack of drugs specifically approved for WM, until the discovery of the BTK inhibitors. Areas covered. Two main therapeutic attitudes are possible: 1) conventional therapies based on combinations with alkylating agents or proteasome inhibitors with steroids and anti-CD20 monoclonal antibodies, or; 2) new approaches with BTK inhibitors, usually alone...
May 17, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29742593/chemokine-receptor-cxcr4-targeted-pet-ct-with-68ga-pentixafor-shows-superiority-to-18f-fdg-in-a-patient-with-waldenstr%C3%A3-m-macroglobulinemia
#4
Yaping Luo, Qingqing Pan, Jun Feng, Xinxin Cao, Fang Li
A 69-year-old woman diagnosed with Waldenström macroglobulinemia (WM) was referred for F-FDG and Ga-Pentixafor PET/CT for evaluation of the disease. Extensive involvement of WM with intense radioactivity in the bone marrow and lymph nodes was found in Ga-Pentixafor PET/CT. However, in F-FDG PET/CT, the lesions showed significantly lower tracer uptake. Given the superiority of Ga-Pentixafor in detecting WM lesions to F-FDG in this patient, Ga-Pentixafor PET/CT might be a promising imaging modality in assessment of tumor burden of WM in future studies...
May 7, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29712895/waldenstr%C3%A3-m-macroglobulinemia-treatment-algorithm-2018
#5
REVIEW
Morie A Gertz
Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma...
May 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29706376/new-treatment-option-for-waldenstr%C3%A3-m-macroglobulinaemia
#6
Manjulika Das
No abstract text is available yet for this article.
April 26, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29703722/-myd88-l265p-mutation-in-lymphoid-malignancies
#7
REVIEW
Xinfang Yu, Wei Li, Qipan Deng, Ling Li, Eric D Hsi, Ken H Young, Mingzhi Zhang, Yong Li
Next-generation sequencing has revealed cancer genomic landscapes, in which over 100 driver genes that, when altered by intragenic mutations, can promote oncogenesis. MYD88 is a driver gene found in hematologic B-cell malignancies. A missense mutation (L265P) changing leucine at position 265 to proline in MYD88 is found in ∼90% of Waldenström macroglobulinemia (WM) cases and in significant portions of activated B-cell diffuse large B-cell lymphomas and IgM monoclonal gammopathy of undetermined significance...
April 27, 2018: Cancer Research
https://www.readbyqxmd.com/read/29686791/lung-consolidation-as-a-rare-presentation-of-lymphoplasmacytic-lymphoma-with-extramedullary-waldenstr%C3%A3-m-s-macroglobulinemia
#8
Omar Abdulfattah, Ebad Ur Rahman, Bikash Bhattarai, Sumit Dahal, Zainab Alnafoosi, David Trauber, Danilo Enriquez, Frances Schmidt
Objectives : Lymphoplasmacytic lymphoma (LPL) is a mature B cell lymphoma that usually involves the bone marrow, spleen and lymph nodes. Extramedullary involvement, including the lung, is rarely reported. Case description : A 73-year-old female initially presented to our hospital complaining of productive cough of white-colour sputum for three weeks duration. She reported unintentional weight loss of ten pounds over the last five months. There was no history of haemoptysis, fever, night sweats, chills, recent infections or hospitalization...
2018: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/29685422/circulating-soluble-receptor-activator-of-nuclear-factor-kappa-b-ligand-and-c-c-motif-ligand-3-correlate-with-survival-in-patients-with-waldenstr%C3%A3-m-macroglobulinemia
#9
Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Dimitrios Christoulas, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Athanasios Papatheodorou, Meletios A Dimopoulos, Evangelos Terpos
BACKGROUND: Serum receptor activator of nuclear factor κB ligand (sRANKL) and chemokine (C-C) motif ligand 3 (CCL-3) have been reported to be elevated in Waldenström macroglobulinemia (WM) patients. However, there are no published data regarding the prognostic value of these molecules in WM regarding progression-free and overall survival. METHODS: To evaluate the effect of these markers of bone remodeling on survival parameters, we prospectively evaluated serum cytokines and biological markers in 55 patients with symptomatic WM before they received any kind of treatment...
March 31, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29674499/true-true-unrelated-coexistence-of-waldenstrom-s-macroglobulinemia-and-cardiac-transthyretin-amyloidosis
#10
Avinainder Singh, Hallie I Geller, Kevin M Alexander, Robert F Padera, Richard N Mitchell, Sharmila Dorbala, Jorge J Castillo, Rodney H Falk
No abstract text is available yet for this article.
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29661775/prospective-clinical-trial-of-ixazomib-dexamethasone-and-rituximab-as-primary-therapy-in-waldenstr%C3%A3-m-macroglobulinemia
#11
Jorge J Castillo, Kirsten Meid, Joshua Gustine, Toni Dubeau, Patricia Severns, Zachary R Hunter, Guang Yang, Lian Xu, Steven P Treon
INTRODUCTION: Proteasome inhibition is of proven efficacy in patients with Waldenström macroglobulinemia (WM). However, WM remains incurable with standard treatments. Novel agents, safe and effective, are needed. METHODS: We designed a prospective phase II study evaluating the combination of ixazomib, dexamethasone and rituximab (IDR) as primary therapy in symptomatic patients with WM. Protocol therapy consisted of oral ixazomib, 4 mg, with intravenous or oral dexamethasone, 20 mg, on days 1, 8 and 15 every 4 weeks for induction cycles 1 and 2, and in combination with intravenous rituximab, 375 mg/m2, on day 1, every 4 weeks for cycles 3 to 6...
April 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29660526/duodenal-scalloping-diagnoses-waldenstr%C3%A3-m-macroglobulinemia
#12
Fadi F Francis, Scott M Kulich, Jana G Hashash
No abstract text is available yet for this article.
April 13, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29656787/fifty-year-incidence-of-waldenstr%C3%A3-m-macroglobulinemia-in-olmsted-county-minnesota-from-1961-through-2010-a-population-based-study-with-complete-case-capture-and-hematopathologic-review
#13
Robert A Kyle, Dirk R Larson, Ellen D McPhail, Terry M Therneau, Angela Dispenzieri, Shaji Kumar, Prashant Kapoor, James R Cerhan, S Vincent Rajkumar
OBJECTIVE: To determine the incidence of Waldenström macroglobulinemia (WM) in a strictly defined geographic area over a 50-year period. PATIENTS AND METHODS: All residents of Olmsted County with a diagnosis of WM, consisting of a monoclonal IgM protein of any size and/or 10% or more lymphoplasmacytic infiltration of the bone marrow along with anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly requiring therapy, were identified from January 1, 1961, to December 31, 2010...
April 12, 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29651281/the-potential-of-isolation-source-to-predict-colonization-in-avian-hosts-a-case-study-in-campylobacter-jejuni-strains-from-three-bird-species
#14
Clara Atterby, Evangelos Mourkas, Guillaume Méric, Ben Pascoe, Helen Wang, Jonas Waldenström, Samuel K Sheppard, Björn Olsen, Josef D Järhult, Patrik Ellström
Campylobacter jejuni is the primary cause of bacterial gastroenteritis worldwide, infecting humans mostly through consumption of contaminated poultry. C. jejuni is common in the gut of wild birds, and shows distinct strain-specific association to particular bird species. This contrasts with farm animals, in which several genotypes co-exist. It is unclear if the barriers restricting transmission between host species of such specialist strains are related to environmental factors such as contact between host species, bacterial survival in the environment, etc...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29650640/-18f-florbetaben-pet-ct-confirms-al-amyloidosis-in-a-patient-with-waldenstr%C3%A3-m-s-macroglobulinaemia
#15
Thomas A Fox, Michael Lunn, Ashutosh Wechalekar, Jamshed Bomanji, Simon Wan, Shirley D'Sa
No abstract text is available yet for this article.
April 12, 2018: Haematologica
https://www.readbyqxmd.com/read/29618689/-osteonecrosis-developing-after-rituximab-containing-chemotherapy-for-waldenstr%C3%A3-m-macroglobulinemia
#16
Fumihiko Nakamura, Risen Hirai, Takashi Higo, Tomiteru Togano, Rieko Sekine
A 71-year-old woman presented with fever, weight loss, and anemia because of recurrent Waldenström macroglobulinemia (WM) with cryoglobulinemia. Treatment with five cycles of doxorubicin, vincristine, cyclophosphamide, and prednisolone (CHOP) therapy was initiated, which resulted in insufficient improvement in anemia. Hence, a combination of rituximab and CHOP therapy was subsequently initiated. The patient complained of lumbago and lower leg pain on day 4 of the chemoimmunotherapy. X-ray findings for the affected sites were unremarkable, and the patient's symptoms gradually and spontaneously subsided...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29610969/bendamustine-and-rituximab-br-versus-dexamethasone-rituximab-and-cyclophosphamide-drc-in-patients-with-waldenstr%C3%A3-m-macroglobulinemia
#17
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, Stephen M Ansell, Shaji Kumar, Sikander Ailawadhi, Rebecca L King, Amber B Koehler, Craig B Reeder, Francis K Buadi, Angela Dispenzieri, Martha Q Lacy, David Dingli, Thomas E Witzig, Ronald S Go, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Nelson Leung, Thomas M Habermann, Suzanne Hayman, Yi Lin, Robert A Kyle, S Vincent Rajkumar, Morie A Gertz, Prashant Kapoor
The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients' MYD88L265P mutation status. Of 160 consecutive patients, 60 received BR (43 with relapsed/refractory WM) and 100 received DRC (50 had relapsed/refractory WM)...
April 3, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29599202/myd88-mutated-and-wild-type-waldenstr%C3%A3-ms-macroglobulinemia-characterization-of-chromosome-6q-gene-losses-and-their-mutual-exclusivity-with-mutations-in-cxcr4
#18
Maria Luisa Guerrera, Nickolas Tsakmaklis, Lian Xu, Guang Yang, Maria Demos, Amanda Kofides, Gloria G Chan, Robert J Manning, Xia Liu, Jiaji G Chen, Manit Munshi, Christopher J Patterson, Jorge J Castillo, Toni Dubeau, Joshua Gustine, Ruben D Carrasco, Luca Arcaini, Marzia Varettoni, Mario Cazzola, Steven P Treon, Zachary R Hunter
No abstract text is available yet for this article.
March 29, 2018: Haematologica
https://www.readbyqxmd.com/read/29589834/hierarchical-involvement-of-myeloid-derived-suppressor-cells-and-monocytes-expressing-latency-associated-peptide-in-plasma-cell-dyscrasias
#19
Tamar Tadmor, Ilana Levy, Zahava Vadasz
Plasma cell dyscrasias (PCD) are disorders of the plasma cells having in common the production of a monoclonal M-protein. They include a spectrum of conditions which may represent a natural progression of the same disease from monoclonal gammopathy of unknown significance (MGUS), to asymptomatic and symptomatic multiple myeloma and plasma cell leukemia and Waldenström's macroglobulinemia (WM). In PCD the immune system is actively suppressed through the secretion of suppressive factors and the recruitment of immune suppressive subpopulations...
March 28, 2018: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/29587222/occupational-extremely-low-frequency-magnetic-fields-elf-mf-exposure-and-hematolymphopoietic-cancers-swiss-national-cohort-analysis-and-updated-meta-analysis
#20
Anke Huss, Adrian Spoerri, Matthias Egger, Hans Kromhout, Roel Vermeulen
PURPOSE: Previous studies have examined risks of leukaemia and selected lymphoid malignancies in workers exposed to extremely low frequency magnetic fields (ELF-MF). Most studies evaluated hematolymphopoietic malignancies as a combined category, but some analyses suggested that effects may be contained to some specific leukaemia or lymphoma subtypes, with inconsistent results. METHODS: We examined exposure to ELF-MF and mortality 1990-2008 from different types of hematolymphopoietic cancers in the Swiss National Cohort, using a job exposure matrix for occupations recorded at censuses 1990 and 2000...
March 24, 2018: Environmental Research
keyword
keyword
99410
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"